Episode 443: ESMO 2025 Bladder Cancer Preview

summaryThis detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan and Levatnib combination versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing. 

This in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of Belzutifan combined with Pembrolizumab, mechanistic insights, biomarker development, and future research directions. 

Today’s episode is focusing on bladder cancer - what you need to know about the pathology, presentation, diagnostic work-up, staging, treatment, and rarer upper GU tract presentations.

We are doing a special episode this week to cover some of the key GU abstracts from ESMO 2024. We cover an update on the STAMPEDE prostate cancer trial, SUNNIFORECAST in non-clear cell renal cell carcinoma, SunRISe-4 in bladder cancer, and more.

Hot off the press: The BOSS (Barrett’s Oesophagus Surveillance Versus Endoscopy at Need Study) randomised control study. Is surveillance really not affecting survival in oesophageal cancer patients? To put things into perspective, we asked Massimiliano Di Pietro, UEG Talks podcas ...  Afficher plus

This is the first of a two part episode on prostate cancer. This episode will cover localized prostate cancer, including the diagnostic work-up, staging and treatment.